Factors affecting patient adherence to highly active antiretroviral therapy

被引:29
作者
Escobar, I
Campo, M
Martín, J
Fernández-Shaw, C
Pulido, F
Rubio, R
机构
[1] Univ Madrid, Hosp 12 Octubre, Dept Pharm, Madrid 28047, Spain
[2] Res Unit, Madrid, Spain
[3] Univ Madrid, Hosp 12 Octubre, Dept Internal Med, HIV Unit, Madrid 28047, Spain
关键词
adherence; antiretroviral treatment;
D O I
10.1345/aph.1C427
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To determine the clinical and demographic variables related to adherence to highly active antiretroviral therapy (HAART) in patients treated in our hospital and identify the characteristics of nonadherent patients. METHODS: Outpatients receiving treatment with HAART (n = 283) were asked about variables related to adherence and to complete the APGAR (family support), State-Trait Anxiety questionnaire (STAI) (emotional situation), and IAS (social support) questionnaires. Patients were classified in 2 groups depending on whether adherence was greater than or equal to95% or <95%. Adherence was defined as the percentage of dosage forms prescribed that were obtained by the patient at the hospital pharmacy. A multivariate analysis was created to analyze how each significant variable affected adherence. RESULTS: Our data showed significant nonadherence for patients with the following factors: low level of education, unemployed, emotional situation, and abuse of substances including intravenous drugs. All significant variables were included in a logistic regression model to optimize the results. This model considered 4 variables: age (95% CI 0.89 to 0.99), number of antiretroviral drugs (95% CI 1.05 to 2.11), STAI Anxiety/Trait test (95% CI 2.02 to 6.02), and abuse of drugs (95% CI 1.20 to 3.95). CONCLUSIONS: We recommended special intervention to reinforce adherence for younger patients, patients taking a high number of antiretroviral drugs, those who have a history of intravenous drug use, and those with high anxiety status.
引用
收藏
页码:775 / 781
页数:7
相关论文
共 35 条
[1]  
ARNSTEN J, 2000, 7 C RETR OPP INF SAN
[2]  
AYCAGUER LCS, 1995, EXCURSION REGRESSION
[3]   COMPLIANCE IN CLINICAL-TRIALS [J].
BESCH, CL .
AIDS, 1995, 9 (01) :1-10
[4]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[5]   Factors affecting adherence to antiretroviral therapy [J].
Chesney, MA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S171-S176
[6]  
Codina C, 1999, FARM HOSP, V23, P215
[7]  
CRAVEN DE, 1990, J ACQ IMMUN DEF SYND, V3, pS45
[8]  
DEEKS S, 1997, 27 INT C ANT AG CHEM
[9]  
ESPINOSA MC, 1996, REV ESP GERIATR GERO, V31, P31
[10]   Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients [J].
Fatkenheuer, G ;
Theisen, A ;
Rockstroh, J ;
Grabow, T ;
Wicke, C ;
Becker, K ;
Wieland, U ;
Pfister, H ;
Reiser, M ;
Hegener, P ;
Franzen, C ;
Schwenk, A ;
Salzberger, B .
AIDS, 1997, 11 (14) :F113-F116